Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | S100B | P04271 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | CHKA | P35790 | 1/20 | 0.49 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736459 | 0.98 | ALDH1A1 (0.68) | ALDH1A1LMNAHTTKDM4EMAPK1 | |
| SCHEMBL5093323 | 0.98 | ALDH1A1 (0.68) | ALDH1A1LMNAHTTKDM4EMAPK1 | |
| SCHEMBL358190 | 0.85 | ALDH1A1 (0.96) | ALDH1A1LMNAHTTKDM4EMAPK1 | |
| SCHEMBL358396 | 0.85 | ALDH1A1 (0.96) | ALDH1A1LMNAHTTKDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL23851874 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAHTTKDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL31587551 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAHTTKDM4EMAPK1 | |
| SCHEMBL360377 | 0.82 | ALDH1A1 (0.93) | ALDH1A1LMNAHTTKDM4EMAPK1 | |
| SCHEMBL28147210 | 0.80 | GAA (0.69) | ALDH1A1LMNAHTTKDM4EMAPK1 | |
| SCHEMBL3538453 | 0.78 | ALDH1A1 (1.00) | ALDH1A1LMNAHTTKDM4EMAPK1 | |
| SCHEMBL9830614 | 0.78 | ALDH1A1 (0.65) | ALDH1A1LMNAHTTKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | claimed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | claimed |
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| CN-120025279-A | Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 | 格雷沃尔夫治疗有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20230064417-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-3883650-A1 | COMPOUNDS | Grey Wolf Therapeutics Limited (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064417-A1 | COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | ALDH1A1 2613/4885LMNA 2596/4885HTT 297/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | ALDH1A1 276/4885LMNA 2582/4885HTT 218/4885 |
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | ALDH1A1 4731/4885LMNA 2742/4885HTT 2335/4885 |
| US-20050004112-A1 | C-fms kinase inhibitors | FLT3, FGR, FER | ALDH1A1 4574/4885LMNA 3031/4885HTT 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.